Alphamab Oncology

English 中文简体中文繁体

English 中文简体中文繁体

Alphamab Oncology Announced Anti-HER2 Bispecific ADC JSKN003 Received Approval from CDE to Initiate a Phase III Clinical Study for Ovarian Cancer

for the all-comer population with platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer who have received 1-4 lines of prior treatment
IND Application for a Phase I/II Clinical Study of Anti-HER2 Bispecific ADC Subcutaneous Co-formulation JSKN033 was Approved

This study has previously been included in the "Pilot Program for Optimizing the Review and Approval of Clinical Trials for Innovative Drugs"
Alphamab Oncology Presented the Phase II Clinical Data of KN046 in Combination with Axitinib for the Treatment of Advanced NSCLC at ESMO IO Congress 2024

Results from Cohort A (previously untreated and PD-L1 TPS≥1%) and cohort B (progressed on CPIs) were reported at this ESMO IO Congress

VISION, MISSION AND CORE VALUES

Our Mission : To make cancer manageable and curable

Our Vision : To develop differentiated, clinically valuable and globally competitive new drugs

Our Core Values : Innovation, Ownership, Integrity, Quality, Growth

Learn More

Proprietary Platforms
Innovative Pipeline
Biologics Manufacturing

WORLD-CLASS BISPECIFIC, ADC AND MIX-MAB PLATFORMS

In complex diseases, such as cancer and viral infection, multiple signaling pathways or mechanisms are involved. Alphamab Oncology has developed several proprietary technical approaches to provide innovative solutions to address this growing trend in the development of modern biotherapeutics.

Learn More

INNOVATIVE PIPELINE WITH SIGNIFICANT POTENTIAL AND MITIGATED DEVELOPMENT RISK

Leveraging its proprietary technology platforms, Alphamab Oncology has developed an exciting pipeline with clear differentiation and global competitiveness.

Learn More

STATE OF ART cGMP MANUFACTURING WITH A SOLID TRACK RECORD

The production of biologics, such as antibody drugs, is a complex, lengthy and costly process. We have established our own cGMP production facilities with strong in house expertise to address the manufacturing issues.

Learn More